Inhibition of (-)-propranolol hydrochloride by its enantiomer in white mice--a placebo-controlled randomized study.
BACKGROUND
A previous pilot study was performed to see if toxicity of (S)-(-)-propranolol hydrochloride may be inhibited by a potentized preparation of its enantiomer. The present study is based on the hypothesis that the toxic effects of an optical isomer, may be counteracted or reversed by the administration of a potentized preparation of one of its stereoisomers, and in particular the enantiomer.


METHODS
508 ICR conventional mice were used. 254 mice were administered (R)-(+)-propranolol HCl homeopathic potency prior to and during the experiment, and the other 254 were administered indistinguishable placebo. On the day of the experiment mice were anesthetized with intraperitoneal Rometar. Once sedated the mice were administered the LD50 dose of (-)-propranolol HCl intraperitoneally.


RESULTS
The end point for statistical analysis was the difference in survival between the placebo and treatment mice. The odds ratio for survival of treatment mice relative to placebo mice was 1.52. The hypothesis of equal survival proportions gave a chi-square of 5.0429 (1 degree of freedom), which has a p-value of 0.0247. The analysis was then adjusted for mouse weight and intraperitoneal (-)-propranolol dosage using a logistic regression (LR) model. The LR treatment odds ratio was 1.51 and the LR treatment chi-square was 4.8112 (1 degree of freedom), which has a p-value of 0.0283. Consequently, we reject the null hypothesis of no treatment effect on survival. Eleven percent more treatment mice survived than placebo mice.


CONCLUSIONS
We conclude that the toxicity of intraperitoneal (-)-propranolol HCl, may be counteracted by administration of a potency of its enantiomer, in ICR conventional mice which have survived preceding intraperitoneal Rometar injection, and pre-dosing with (+)-propranolol HCl homeopathic potency.
Kuzeff
R M
RM
Graduate School of Integrative Medicine, Swinburne University of Technology, Melbourne, Australia. kuzeffm@ausdoctors.org
Mecheva
R P
RP
Topashka-Ancheva
M N
MN
D000319:Adrenergic beta-Antagonists / Q000737:chemistry / Q000633:toxicity; D000818:Animals; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006705:Homeopathy; D007274:Injections, Intraperitoneal; D007928:Lethal Dose 50; D016015:Logistic Models; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010919:Placebos; D011433:Propranolol / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000633:toxicity; D011897:Random Allocation; D013237:Stereoisomerism; D016019:Survival Analysis
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D011433:Propranolol